

UC Berkeley

UC Berkeley Previously Published Works

Title

Efficient production of oxidized terpenoids via engineering fusion proteins of terpene synthase and cytochrome P450

Permalink

<https://escholarship.org/uc/item/0hs3c6kw>

Authors

Wang, Xi

Pereira, Jose Henrique

Tsutakawa, Susan

et al.

Publication Date

2021-03-01

DOI

10.1016/j.ymben.2021.01.004

Peer reviewed

1 **Efficient production of oxidized terpenoids via engineering fusion proteins of terpene**
2 **synthase and cytochrome P450**

3

4 Xi Wang^{1,2}, Jose Henrique Pereira^{1,3}, Susan Tsutakawa³, Xinyue Fang^{1,2,4}, Paul D. Adams^{1,3,5},
5 Aindrila Mukhopadhyay^{1,2}, Taek Soon Lee^{1,2,*}

6

7 ¹ Joint BioEnergy Institute (JBEI), 5885 Hollis St., Emeryville, CA 94608, USA

8 ² Biological Systems & Engineering Division, Lawrence Berkeley National Laboratory,
9 Berkeley, CA 94720, USA

10 ³ Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory,
11 Berkeley, CA 94720, USA

12 ⁴ Department of Molecular & Cell Biology, University of California, Berkeley, CA 94720, USA

13 ⁵ Department of Bioengineering, University of California, Berkeley, CA 94720, USA.

14

15 * Corresponding author, Joint Bioenergy Institute, 5885 Hollis Street, Emeryville, CA 94608,
16 USA.

17 E-mail address: tslee@lbl.gov (T. S. Lee). Tel: +1-510-495-2470. Fax: +1-510-495-2629.

18

19

20

21 **Abstract**

22 The functionalization of terpenes using cytochrome P450 enzymes is a versatile route to the
23 production of useful derivatives that can be further converted to value-added products. Many
24 terpenes are hydrophobic and volatile making their availability as a substrate for P450 enzymes
25 significantly limited during microbial production. In this study, we developed a strategy to
26 improve the accessibility of terpene molecules for the P450 reaction by linking terpene synthase
27 and P450 together. As a model system, fusion proteins of 1,8-cineole synthase (CS) and P450_{cin}
28 were investigated and it showed an improved hydroxylation of the monoterpene 1,8-cineole up
29 to 5.4-fold. Structural analysis of the CS-P450_{cin} fusion proteins by SEC-SAXS indicated a
30 dimer formation with preferred orientations of the active sites of the two domains. We also
31 applied the enzyme fusion strategy to the oxidation of a sesquiterpene epi-isozizaene and the
32 fusion enzymes significantly improved albaflavenol production in engineered *E. coli*. From the
33 analysis of positive and negative examples of the fusion strategy, we proposed key factors in
34 structure-based prediction and evaluation of fusion enzymes. Developing fusion enzymes for
35 terpene synthase and P450 presents an efficient strategy toward oxidation of hydrophobic terpene
36 compounds. This strategy could be widely applicable to improve the biosynthetic titer of the
37 functionalized products from hydrophobic terpene intermediates.

38

39

40 **Keywords**

41 Oxidized terpenoid, fusion protein, terpene synthase, P450, SAXS, I-TASSER

42 **1. Introduction**

43 Terpenes are a large class of natural products, primarily produced by plants and constitute the
44 main components of essential oils. A typical monoterpene (C_{10}), such as limonene, is a cyclic
45 hydrocarbon molecule ($C_{10}H_{16}$) and can be used as a precursor of fuel additives, fragrances,
46 insecticides, and pharmaceuticals (Aharoni et al., 2005). Production of terpenes in the microbial
47 system is considered a more sustainable and stable alternative to the isolation from plants or via
48 chemical synthesis. Functionalization of the terpene carbon backbone by enzymes such as
49 cytochrome P450s could further expand the range of bio-based compounds which frequently can
50 be converted to additional products of commercial interest (Bernhardt, 2006; Chang et al., 2007;
51 Pateraki et al., 2015; Renault et al., 2014; Urlacher and Girhard, 2019). For example, limonene
52 can be oxidized by P450 (CYP153) to perillyl alcohol, a precursor of promising anti-cancer
53 agents (van Beilen et al., 2005). While P450s play an important role in the decoration and
54 modification of terpenes essential for the new bioactivities, the hydrophobicity and volatility of
55 terpene molecules might limit the availability of the substrate around the enzyme and result in
56 low enzymatic conversion during microbial production, especially when a solvent overlay is
57 used to reduce the loss of these volatile compounds via extraction of hydrophobic terpenes to the
58 overlay (Alonso-Gutierrez et al., 2013). This makes the subsequent enzymatic reaction (which
59 uses terpenes as substrates) less efficient and eventually lowers the titer of the final product.

60 To overcome the low availability of hydrophobic substrates for downstream enzymes such as
61 P450s, one popular strategy is to create a spatial constraint that improves the proximity between
62 the enzyme and the substrate (Conrado et al., 2008). Engineering of fusion proteins (Kourtz et
63 al., 2005; Meynial Salles et al., 2007), protein scaffolds (Dueber et al., 2009), and
64 compartmentalization of metabolic pathways (Avalos et al., 2013) have been explored to achieve

65 the proximity effect. Among these approaches, engineering synthetic fusion proteins have been
66 extensively used to modify enzymes toward efficient metabolic catalysis due to their simplicity
67 and effectiveness (Yu et al., 2015). Using a short peptide linker sequence, two or more enzymes
68 are combined and generate a single polypeptide that exhibits more than one activity or increases
69 the reaction rate for consecutive enzymes. In the microbial production of isoprenoids, a higher
70 pinene production level was reported by linking terpene synthase with geranyl pyrophosphate
71 (GPP) synthase to overcome product inhibition from GPP (Sarria et al., 2014). Similarly, an
72 engineered fusion of isopentenyl diphosphate (IPP) isomerase and isoprene synthase showed a
73 3.3-fold increase of isoprene titer (Gao et al., 2016). For P450 enzymes, fusions of P450 with a
74 heterologous cytochrome P450 reductase have also proven successful in various instances. For
75 example, a P450 TxtE was linked to the reductase domain of P450BM3 for improved activity
76 and regio-promiscuity in aromatic nitration (Zuo et al., 2017).

77 Although engineering a fusion of P450 with a cytochrome P450 reductase is widely studied,
78 there are fewer reports for engineering a fusion between P450 and a terpene synthase. Given that
79 the considerable loss of the terpene substrate from the cell is a critical limitation for the
80 subsequent P450 reaction during the microbial production (Alonso-Gutierrez et al., 2013),
81 engineering a fusion protein by linking terpene synthase and P450 to form a chimeric protein
82 could improve the proximity of P450 and the terpene substrate, which in turn would improve the
83 substrate availability for P450. In this study, we selected the hydroxylation of monoterpene 1,8-
84 cineole as a model system to demonstrate this approach in the microbial system via engineering
85 the recombinant enzyme fusion between terpene synthase-P450 enzyme fusion (Figure 1).
86 Guided by structural modeling, we engineered a series of fusion proteins between 1,8-cineole
87 synthase and P450_{cin} (CYP176A1) to investigate the hydroxylation of 1,8-cineole in both *in vitro*

88 and *in vivo* conditions in comparison to non-fused enzymes. Structural analysis of fusion proteins
89 revealed that different linker length changes the flexibility of the fusion enzymes. We also
90 applied this enzyme fusion strategy for the oxidation of several other terpenes, and the data from
91 both experiments and the modeling analysis, of positive and negative results suggested key
92 factors (e.g. linker length, enzyme orientation, etc.) for designing a fusion protein. Our results
93 demonstrated that engineering fusion enzyme is a feasible strategy for the efficient production of
94 functionalized products from hydrophobic terpene intermediates.

95

96 **2. Material and methods**

97 **2.1 Strains and plasmid construction**

98 All strains and plasmids used in this study are listed in Table 1. Strains and plasmids along with
99 their associated information have been deposited in the public domain of the JBEI Registry
100 (<https://public-registry.jbei.org>; entries JPUB_016968 to JPUB_017025) and are available from
101 the authors upon request. *E. coli* DH1 strain was used for terpene and oxidized terpene
102 production, and *E. coli* DH5 α was used for genetic cloning. Genes of CinA (P450_{cin},
103 CYP176A1; GenBank ID: AF456128) and CinC (Cindoxin, Cdx, GenBank ID: AF456128) from
104 *Citrobacter braakii*, and CYP170A1 (*sco5223*; GenBank ID: NC_003888) from *Streptomyces*
105 *coelicolor* A3(2) were codon-optimized and synthesized by Integrated DNA Technologies, Inc.
106 (San Diego, CA, USA). Fpr (GenBank ID: CP032667) was cloned from *E. coli* genomic DNA.
107 CS from *Streptomyces clavuligerus* was cloned from plasmid JBEI-15065 (Table 1). All peptide
108 linkers were introduced onto the plasmid by PCR using primers listed in Supplementary Table
109 S1.

110

111 **2.2 Protein expression and purification**

112 A plasmid pSKB3 encoding interested proteins with N-terminal His-tag was transformed into *E.*
113 *coli* BL21 (DE3). BL21 (DE3) strains bearing pSKB3 plasmids were cultured in Lysogeny Broth
114 (LB) medium containing 50 $\mu\text{g/mL}$ kanamycin at 37°C until the optical density of the culture at
115 600 nm (OD_{600}) reached to 0.5 – 0.8. The culture was then supplemented with 0.4 mM isopropyl
116 β -D-1-thiogalactopyranoside (IPTG) for induction and transferred to 18°C for culturing
117 overnight. Cells were collected by centrifugation and resuspended in 25 mM Tris-HCl (pH 8.0)
118 buffer containing 300 mM NaCl and 10 mM imidazole (pH 8.0). Cells were lysed by sonication
119 and proteins were purified using Ni-NTA Agarose (QIAGEN, Hilden, Germany). All purified
120 proteins were desalted in 25 mM Tris-HCl (pH 8.0) buffer containing 100 mM NaCl, and 10%
121 glycerol, and stored at -80°C. A Bradford assay (Sigma-Aldrich, St. Louis, MO, USA) was used
122 to quantify the protein concentration of purified proteins, with bovine serum albumin (BSA) as a
123 standard. The quantification of P450_{cin} was determined by UV absorption at 415 nm ($\epsilon = 150$
124 $\text{cm}^{-1}\text{mM}^{-1}$) (Slessor et al., 2012), and for redox proteins: Cdx at 456 nm ($\epsilon = 10825 \text{ cm}^{-1}\text{M}^{-1}$)
125 (Hawkes et al., 2010), Fpr at 456 nm ($\epsilon = 7100 \text{ cm}^{-1}\text{M}^{-1}$) (Jenkins and Waterman, 1994). Both
126 quantification results were shown in the Supplementary Table S4.

127

128 **2.3 *In vitro* production of hydroxycineole**

129 Using purified proteins, Bradford-quantified non-fusion (5 μM CS + 5 μM CinA) or fusion
130 proteins (5 μM) were used for the *in vitro* production of hydroxycineole with 40 μM CinC and
131 10 μM Fpr in 50 mM Tris-HCl buffer (pH 7.4) containing 5 mM MgCl_2 (Hawkes et al., 2010;
132 Shaw et al., 2015). NADPH (2 mM) and 1 mM geranyl pyrophosphate (GPP, Sigma-Aldrich

133 19533) were added to start the reaction. The reaction was conducted in a total volume of 600 μ L
134 reaction in a 1.7-mL microcentrifuge tube at 25°C for 5 hours.

135

136 **2.4 *In vivo* production of hydroxycineole**

137 *E. coli* DH1 bearing two plasmids (JBEI-3122 + JPUB_016986 to JPUB_010998, Table 1) was
138 used for hydroxycineole production. Starter cultures of all production strains were prepared by
139 growing single colonies in LB medium containing 30 μ g/mL chloramphenicol and 100 μ g/mL
140 carbenicillin at 37°C with 200-rpm shaking for overnight. The starter cultures were diluted in 5
141 mL EZ-Rich defined medium (Teknova, CA, USA) containing 10 g/L glucose (1%, w/v), 30
142 μ g/mL chloramphenicol, 100 μ g/mL carbenicillin, and 0.5 mM IPTG in 50-mL test tubes. 0.5
143 mL nonane (10%, v/v) was added when required as a solvent overlay. The *E. coli* cultures were
144 incubated in rotary shakers (200 rpm) at 30°C for 48 hours.

145

146 **2.5 *In vivo* production of oxidized epi-isozizaene**

147 *E. coli* DH1 bearing two plasmids (JBEI-2704 + JPUB_017000 to JPUB_017009, Table 1) was
148 used for oxidized epi-isozizaene production. Starter cultures of all production strains were
149 prepared by growing single colonies in LB medium containing 30 μ g/mL chloramphenicol and
150 100 μ g/mL carbenicillin at 37°C with 200-rpm shaking for overnight. The starter cultures were
151 diluted in 5 mL EZ-Rich defined medium (Teknova, CA, USA) containing 10 g/L glucose (1%,
152 w/v), 30 μ g/mL chloramphenicol, 100 μ g/mL carbenicillin, and 65 mg/L δ -aminolevulinic acid,
153 0.5 mM IPTG in 50-mL culture tubes. 0.5 mL nonane (10%, v/v) was added when required as a
154 solvent overlay. The *E. coli* cultures were incubated in rotary shakers (200 rpm) at 30°C for 72
155 hours.

156

157 **2.6 Protein structure prediction**

158 Structures of fusion proteins were predicted by Iterative Threading ASSEmblY Refinement (I-
159 TASSER) server (Roy et al., 2012; Yang and Zhang, 2015; Zhang, 2009). The predicted models
160 with the highest C-score were used for further analysis. For the non-fusion enzyme CS (PDB:
161 5NX6) (Karuppiyah et al., 2017), P450_{cin} (PDB: 1T2B) (Mehareenna et al., 2004), EizS (PDB:
162 3KB9) (Aaron et al., 2010), CYP170A1 (PDB: 3DBG) (Zhao et al., 2009), LS (PDB: 2ONG)
163 (Hyatt et al., 2007), and CYP153A6 (similar sequence to CYP153A7, PDB: 3RWL) (Pham et al.,
164 2012), their structural models or homology model were retrieved from PDB and aligned with the
165 predicted structures of correlated fusion proteins. Active sites of subunits in the fusion proteins
166 were annotated according to literature. PyMOL was used for visualization and image generation.

167

168 **2.7 Small Angle X-ray Scattering (SAXS)**

169 Size Exclusion Chromatography (SEC) coupled to Small Angle X-ray Scattering (SAXS) data
170 were collected at the beamline 12.3.1 at the Advanced Light Source synchrotron (Lawrence
171 Berkeley National Laboratory, Berkeley, CA, USA) (Classen et al., 2013). Proteins were
172 separated on an SEC Shodex KW-803 column at 20°C in 25 mM Tris HCl, pH 7.5, 50 mM NaCl
173 and eluted directly into the SAXS sample cell at a flow rate of 0.5 mL/min. Three second X-ray
174 exposures were collected continuously over the 30 minutes SEC elution at 1.127Å wavelength
175 on a Dectris PILATUS3 × 2M detector. Initial data were processed at the beamline (Dyer et al.,
176 2014; Hura et al., 2009). The sample to detector distance was 2.105 m. The SAXS eluent was
177 split 4 to 1 between the SAXS sample cell and UV, multi-angle light scattering (MALS), and
178 refractometer, measured on an 18-angle DAWN HELEOS II light scattering detector and Optilab

179 refractive index concentration detector (Wyatt Technology, CA, USA). The system was
180 calibrated with bovine serum albumin (BSA). Background subtraction from SAXS frames after
181 the protein peaks and evolving factor analysis (EFA) was done using the program RAW.
182 Representing tetrameric, dimeric, and monomeric population, three components were derived
183 from the peak eluting at ~20 minutes. SAXS frames after the main peak were used for buffer
184 subtraction. The targeted elution peak was deconvoluted into three components, representing
185 monomer, dimer, and tetramer. Further SAXS analysis was done using RAW (Volume of
186 Correlation MW) (Rambo and Tainer, 2013), SCÅTTER (Porod component,
187 <https://bl1231.als.lbl.gov/scatter/>), ATSAS (Guinier, Real space, GASBOR) (Franke et al.,
188 2017). In the Guinier plots, all SAXS curves were linear, consistent with no aggregation present.
189 Based on the crystal structures of the subunits (PDB: 5NX6 and 1T2B), SAXS models were built
190 using MODELER (Fiser et al., 2000), followed by BilBOMD/FOXS (Pelikan et al., 2009;
191 Schneidman-Duhovny et al., 2016, 2013). SAXS data collection and data analysis details are
192 provided in Table 2.

193

194 **2.8 Gas chromatography-mass spectrometry (GC-MS) analysis**

195 For 1,8-cineole, hydroxycineole, and perillyl alcohol, samples were extracted by an equal
196 volume of ethyl acetate containing β -pinene (5 mg/L) as an internal standard. For epi-isozizaene
197 and oxidized products, samples were extracted by an equal volume of ethyl acetate containing
198 guaiiazulene (5 mg/L) as an internal standard. The mixture of ethyl acetate and *in vitro* reaction
199 solution or cell culture was vigorously shaken for 15 min and subsequently centrifuged at 21,130
200 g for 3 min to separate ethyl acetate from the aqueous phase. The ethyl acetate layer was
201 collected and 1 μ L was analyzed by Agilent GC-MS equipped with HP-5 column (Agilent,

202 USA). The GC oven was programmed from 40°C (held for 3 min) to 295°C at 15°C/min. The
203 solvent delay was set at 3.4 min. 1,8-cineole and perillyl alcohol were quantified using authentic
204 standards. Hydroxycineole concentration was estimated using total ion chromatogram (TIC)
205 areas with respect to the TIC areas of alternative standard 1,8-cineole, and β -pinene (a
206 monoterpene) as an internal standard to normalize the GC results. Similarly, the concentrations
207 of epi-isozizaene, albaflavenol, and albaflavenone were estimated using their TIC areas with
208 respect to the TIC areas of alternative standard (-)-trans-caryophyllene, and guaiazulene (a
209 sesquiterpene) was used as an internal standard to normalize the GC results. MS full scan
210 spectrum of hydroxycineole and oxidized epi-isozizaene were shown in Supplementary Figures
211 S1 and S2. When nonane overlay was used during the production, the solvent delay was set at
212 6.8 min. Both the nonane overlay and the aqueous phase of the culture were sampled for the GC-
213 MS measurement, respectively. The production titers were the sum of both measured values after
214 applying the dilution factor.

215

216 **3. Results**

217 **3.1 Designing fusion enzymes of 1,8-cineole synthase and P450_{cin}**

218 1,8-Cineole, or eucalyptol, is a monoterpene (C₁₀) naturally found in essential oils from
219 *Eucalyptus globulus* and other plants. (Klocke et al., 1987; Shaw et al., 2015). 1,8-Cineole is also
220 a potential precursor for high energy-density molecules used as jet fuels (Bergman and Siewers,
221 2016; Yang et al., 2017), and therefore *E. coli* was engineered previously to overproduce 1,8-
222 cineole using the mevalonate (MVA) pathway (Mendez-Perez et al., 2017). Hydroxylation of
223 1,8-cineole introduces a functional group to this compound and allows further derivatization to
224 more valuable products, such as *p*-cymene (Leita et al., 2010). P450_{cin} (CYP176A1) from *C.*

225 *braakii* has shown a specific activity of 1,8-cineole hydroxylation to produce (1*R*)-6 β -
226 hydroxycineole (or hydroxycineole) (Hawkes et al., 2002), and its redox partners, NADPH-
227 dependent flavodoxin reductase and a flavodoxin, have also been reported (Hawkes et al., 2010).

228 To investigate the hydroxylation of 1,8-cineole as a model system for engineering the
229 enzyme fusion between terpene synthase and P450, fusion proteins were designed between 1,8-
230 cineole synthase (CS) and P450_{cin} using a flexible peptide linker Gly-Ser-Gly (GSG) (Guo et al.,
231 2017). First, we have predicted the structure of CS-P450_{cin} fusion proteins linked by (GSG)_n
232 linkers using the I-TASSER server (Roy et al., 2012; Yang and Zhang, 2015; Zhang, 2009). The
233 modeling provided a possible orientation of the CS and P450_{cin} fusion proteins (Figure 2), and
234 the results showed that the two active sites of CS and P450_{cin} were proximally oriented. Based on
235 the preliminary structural analysis of CS-P450_{cin} fusion proteins, we engineered five CS-P450_{cin}
236 fusion proteins with different linker lengths by adjusting the repeat number (n) of (GSG)_n linker
237 (n = 1–5), and the resultant CS-P450_{cin} fusion proteins were named G1 to G5, respectively
238 according to their number of GSG linker repeats.

239

240 **3.2 *In vitro* production of hydroxycineole with CS-P450_{cin} fusions from GPP**

241 To investigate the hydroxylation of 1,8-cineole by various CS-P450_{cin} fusions with different
242 linker lengths, equal moles of purified proteins were used for *in vitro* production of
243 hydroxycineole from GPP substrate (Figure 3). In a 5-hour reaction, most CS-P450_{cin} fusions
244 except G1 showed a higher level of hydroxycineole production than non-fused individual CS and
245 P450_{cin}. The G1 fusion did not show a substantial difference relative to the non-fusion control
246 (Figure 3C). The highest level of hydroxycineole production was observed from the G4 fusion
247 and showed a 5.4-fold increase over non-fused CS and P450_{cin} after 5 hours. The highest

248 hydroxycineole production rate in G4 was reached after 2 hours at 0.051 $\mu\text{M}/\text{min}$, which is 6.4-
249 fold faster than that of the non-fusion enzymes (0.008 $\mu\text{M}/\text{min}$). The overall hydroxylation ratio
250 of the G4 fusion was 2.3% after 5 hours, which is 5.4-fold higher than that of the non-fusion
251 enzymes (0.4%) (Figure 3D). All 5 fusion enzymes also showed up to a 2.7-fold increase of 1,8-
252 cineole level over the non-fused enzymes during the first 3 hours (Figure 3C), suggesting that
253 enzyme fusion also improves the activity of the cineole synthase and eventually more terpene
254 substrate is available for the P450 reaction with the fusion proteins. Likely due to the volatility of
255 1,8-cineole, it was also observed that 1,8-cineole eventually decreased to a similar level from all
256 different samples after a 3-hour reaction (Figure 3C).

257 The *in vitro* production results with the engineered CS-P450_{cin} fusions showed higher
258 hydroxycineole production than non-fused CS and P450_{cin}. The improved 1,8-cineole
259 hydroxylation from fusion proteins could be attributed to the proximity of P450_{cin} to its
260 hydrophobic substrate 1,8-cineole, which shows the advantage of linking a P450 enzyme to a
261 terpene synthase, particularly when a hydrophobic and volatile terpene is the intermediate and
262 served as the substrate for a consequential P450 reaction during a multi-step terpene oxidation.
263

264 **3.3 *In vivo* assessment of CS-P450_{cin} fusions for hydroxycineole production from glucose**

265 To *in vivo* assess hydroxycineole production using fusion enzymes, the CS-P450_{cin} fusions
266 were introduced into *E. coli*. Informed from the previous report (Mendez-Perez et al., 2017), *E.*
267 *coli* strain containing 2 separate plasmids was used for hydroxycineole production by inserting
268 the genes encoding the P450_{cin} (CinA) and its redox partner Cdx (CinC) downstream of CS on
269 the 2nd plasmid JBEI-15065 (Table 1). For the expression of the non-fused CS and P450_{cin}, an
270 RBS sequence (5'-TTTAAGAAGGAGATATAC-3') was used for individual expression of CS

271 and P450_{cin}, respectively (Table 1 and Supplementary Table S1). For the CS-P450_{cin} fusions, the
272 same RBS was used for the entire fused gene sequence. As solvent overlay is usually used to
273 prevent evaporation of the product during production, we used the overlay to evaluate the
274 performance of fusion enzymes at the *in vivo* conditions. While dodecane was used as the
275 overlay for 1,8-cineole production previously (Mendez-Perez et al., 2017), it has a similar
276 molecular weight to hydroxycineole (MW=170), as well as a close retention time in
277 chromatography. Therefore, we used nonane instead of dodecane as the overlay to obtain a better
278 signal of hydroxycineole by GC-MS.

279 As shown in Figure 4, the use of solvent overlay generally facilitated 1,8-cineole production,
280 but it did not help hydroxycineole levels. For both non-fusion and fusion proteins,
281 hydroxycineole production without using overlay was 1.7 to 3.3-fold higher than that with an
282 overlay. When nonane overlay was used, all fusions except G4 detected more hydroxycineole
283 than the non-fusion control strain (Figure 4C), while generally less amount of 1,8-cineole (except
284 for G2), suggesting an inefficient hydroxylation in the non-fusion control strain. When overlay
285 was not used during the production, all 5 strains with fusion protein produced more
286 hydroxycineole than the non-fusion control strain (Figure 4C). The highest hydroxycineole titer
287 was observed from G3 (56 mg/L), which is 3.1-fold higher than that of the non-fusion control
288 (18 mg/L). In contrast to the *in vitro* results, G4 did not show any significant advantage
289 compared with the other fusions with different linker lengths. Similar to our previous work of a
290 P450 conversion perillyl alcohol from limonene (Alonso-Gutierrez et al., 2013), the addition of
291 solvent overlay facilitated the *in situ* extraction of 1,8-cineole and prevents the evaporation from
292 the culture, but it also competed with the subsequent P450 enzymatic reaction for terpene
293 substrates and eventually lower the P450 bioconversion efficiency. Overall, the use of fusion

294 proteins improved the production of hydroxycineole with and without added solvent overlay,
295 which suggested a higher efficiency during *in vivo* production of the oxidized terpene.

296 In addition to the linker length, the enzyme orientation is another key factor for the activity
297 of a fusion enzyme (Sarria et al., 2014). Given that G3 showed high production of
298 hydroxycineole both *in vitro* and *in vivo* conditions, we used the (GSG)₃ linker to construct a
299 fusion enzyme P450_{cin}-(GSG)₃-CS by switching the order of CS and P450_{cin} and to test
300 hydroxycineole production. Compared to the CS-(GSG)₃-P450_{cin} fusion (G3), this fusion enzyme
301 with reversed domain order produced 51% and 76% less 1,8-cineole and hydroxycineole,
302 respectively when the overlay was used (Table 3). These trends were also significant when the
303 overlay was not used. In this case, it produced 80% and 63% less 1,8-cineole and
304 hydroxycineole, respectively, than in the G3 fusion protein (Table 3), indicating the inefficiency
305 when CS and P450_{cin} were linked in the reversed orientation. This P450_{cin}-(GSG)₃-CS fusion
306 enzyme did not even result in a significant improvement of hydroxycineole but less 1,8-cineole
307 production compared with the non-fusion control strain (Table 3). Structural modeling results
308 suggested that the two active sites of P450_{cin} and CS in this fusion protein are no longer
309 proximally oriented (Supplementary Figure S3). As shown in Figure S3A, the active site of CS
310 faces outside of the fusion complex surface, whereas the active site of P450_{cin} is located in the
311 middle of the fusion complex. Thus, the simulated fusion structure shows an unfavorable
312 orientation for the two subunits and may explain its less efficiency as a fusion protein.

313

314 **3.4 Structural characterization of CS-P450_{cin} enzyme fusions**

315 To experimentally determine the orientation of CS and P450_{cin}, we used Size Exclusion
316 Chromatography coupled to Small Angle X-ray Scattering (SEC-SAXS) to characterize the G3

317 and G4 fusion proteins in solution as these two fusion enzymes showed the best activities at the
318 *in vitro* experiments. SAXS measures electron pair distances of proteins in solution and can
319 reveal protein stoichiometry, flexibility, and overall orientation, in cases such as ours where the
320 individual subunits have been crystallized (Putnam et al., 2007). For both G3 and G4 fusion
321 proteins in the size exclusion chromatography profile, the proteins eluted in multiple peaks, with
322 the earliest peak representing large aggregates and the second major peak representing a mixture
323 of monomer, dimer, and tetramer, based on SAXS molecular mass calculation and in agreement
324 with in-line Multi-Angle Light Scattering (MALS) measurements (Figure 5A).

325 For the G3 fusion protein, the aggregate peak was higher in the UV signal than the
326 monomer/dimer peak, but the second peak was larger than the aggregate peak in the G4 fusion
327 protein (Figure 5A). The different proportions of peaks suggested that the G3 fusion protein may
328 be more constrained than the G4 fusion protein. The SAXS frames from the second peaks were
329 deconvoluted into three SAXS components, representing monomer, dimer, and tetramer. For
330 both G3 and G4 fusion proteins, the dimer population was greater than monomer or tetramer,
331 based on MALS and relative intensity of the scattering profile, even taking into account the
332 greater scattering of the dimer compared to the monomer. A measure of the protein density and
333 relative flexibility, the Porod Debye number for the G4 monomer and dimer were both 3.3
334 (Table 2), consistent with the protein behaving like beads on a string (Brosey et al., 2013; Rambo
335 and Tainer, 2011). The number for the G3 monomer and dimer were 3.9 and 3.4 (Table 2),
336 respectively, indicating greater rigidity in the G3 fusion protein.

337 Using two different modeling programs followed by molecular dynamics, we generated
338 models of the G3 and G4 monomer and dimer to match against the experimental SAXS data
339 (Figure 5B and 5C). The analysis compares single models and ensembles of models, the latter of

340 which are usually found to best fit experimental SAXS data when there is significant flexibility.
341 Surprisingly, we found that the experimental SAXS data curves fit well against single models,
342 despite the flexibility indicated by the Porod Debye number in three of the SAXS curves. This
343 SAXS modeling result suggests the two domains of CS and P450_{cin} are shifting relative to each
344 other but not completely swinging free (Figure 5D). For the monomer of fusion proteins, the
345 SAXS structural analysis matched the predicted structure by I-TASSER for the fusion protein
346 sequence (Figure 2), and the formalized dimers of fusion protein could also intensify the
347 proximity effect.

348

349 **3.5 Production of oxidized epi-isozizaene using enzyme fusions.**

350 We applied the enzyme fusion strategy to the biosynthetic pathway for oxidized epi-
351 isozizaene products (Figure 1, Figure 6) such as albaflavenol, and the subsequently oxidized
352 product albaflavenone, a sesquiterpene antibiotic found in *S. coelicolor* A3(2) (Zhao et al.,
353 2008). A bacterial P450 (CYP170A1) has been identified to catalyze the oxidation of epi-
354 isozizaene in *S. coelicolor* A3(2). Recently, epi-isozizaene biosynthesis was successfully
355 engineered in *E. coli* to produce a novel jet-fuel precursor using the MVA pathway (Liu et al.,
356 2018). To build the fusion protein for epi-isozizaene synthase (EizS) and CYP170A1, we
357 predicted the possible structure of an EizS-CYP170A1 fusion protein, and it showed the
358 proximal orientation for the two active sites of EizS and CYP170A1 in the fusion
359 (Supplementary Figure S4). Following the fusion enzyme engineering strategy used in
360 hydroxycineole biosynthesis, we constructed fusions for EizS and CYP170A1 with 1 to 5 repeats
361 of Gly-Ser-Gly (GSG) peptide linker. An RBS sequence (5'- TTTACACAGGAAACAGACC-
362 3') was used for the expression of EizS and CYP170A1 individually in the non-fusion control

363 strain similar to the 1,8-cineole oxidation case. For the EizS-CYP170A1 fusions, the same RBS
364 was used for the entire fused gene sequence (Table 1, Supplementary Table S1).

365 Compared with the non-fusion control, the epi-isozizaene production level was a little lower
366 in the strains engineered with fusion enzymes (Figure 6C). On the other hand, the total oxidized
367 products (albaflavenol and albaflavonone) were notably increased in the fusions with shorter
368 linkers (GSG)₁₋₃ for both conditions, with and without added solvent overlay (Figure 6D). As
369 expected, the improvement of oxidized products by enzyme fusions was more significant when
370 the overlay was used. The highest oxidized epi-isozizaene level (13 mg/L albaflavenol, 3 mg/L
371 albaflavonone) was observed by the fusion EizS-(GSG)₂-CYP170A1 with a (GSG)₂ linker,
372 which achieved 90- and 2.3-fold increase in albaflavenol and albaflavonone production,
373 respectively. This result demonstrated the viability of engineering a fusion protein between
374 terpene synthase and P450 for sesquiterpene oxidation, suggesting possible applications of this
375 enzyme fusion strategy to functionalize diverse terpenoid compounds.

376

377 **4. Discussion**

378 In this study, we used an enzyme fusion strategy by directly linking terpene synthase and
379 cytochrome P450 to facilitate the heterologous production of oxidized terpenoids in engineered
380 microbial systems. Unlike the natural biosynthesis process in plants (Cheng et al., 2007; Pateraki
381 et al., 2015), engineered microbial systems usually lack cellular compartments and spatial
382 regulation to contain the volatile molecules. By taking advantage of the proximal environment
383 created by the fusion enzyme, we expected the fusion can facilitate the capture of volatile terpene
384 molecules for downstream P450s and improve the terpene oxidation. Using the monoterpene 1,8-
385 cineole hydroxylation as a model system, fusion proteins of 1,8-cineole synthase (CS) and

386 P450_{cin} (CYP176A1) were constructed with different lengths of peptide linkers. The engineered
387 CS-P450_{cin} fusions showed improved hydroxylation of 1,8-cineole at both *in vitro* and *in vivo*
388 conditions. During the *in vitro* hydroxycineole production, all CS-P450_{cin} fusions showed a faster
389 accumulation of 1,8-cineole than the non-fused individual enzyme case (Figure 3C). This might
390 be a result from a reduced loss of 1,8-cineole in the proximal environment created by the fusion
391 enzyme that facilitates the capture of 1,8-cineole and reduces the diffusion loss in solution. The
392 increased availability of the terpene substrate could be a key factor that leads to higher
393 production rates observed for P450_{cin} in fusion proteins (Supplementary Table S3), which
394 indicated that the non-fused P450_{cin} could remain in a suboptimal activity in a two-step terpene
395 oxidation. As many terpenes are usually hydrophobic and volatile compounds, the availability of
396 terpene substrates is critical to reaching the maximum activity for a consequent P450 enzyme in
397 the multi-step enzymatic oxidation of terpenoids. Additionally, the nature of CS dimerization
398 (Karuppiyah et al., 2017) could play an important role in enhancing the entire activity of a CS-
399 P450_{cin} fusion protein. Similar results were reported in a fusion of *E. coli* beta-galactosidase
400 (LacZ) and the dimeric galactose dehydrogenase (GalDH) from *Pseudomonas fluorescens*,
401 which showed improved enzyme activities when they are linked to each other (Ljungcrantz et al.,
402 1989).

403 While spatial proximity explains the most advantages of a fusion protein relative to the
404 corresponding non-fused enzymes, we observed fusion proteins with different linker lengths
405 showed distinct activities. Surprisingly, the best fusion protein (G4) with 4-repeats of Gly-Ser-
406 Gly linker from the *in vitro* conditions did not show the best production level under the *in vivo*
407 conditions (Figure 3C, Figure 4C). This indicated that the optimal linker length for a fusion
408 protein may vary from the *in vitro* and *in vivo* conditions because of their inconsistent reaction

409 conditions, such as the ratio of P450_{cin} and redox partners. This may also suggest that an optimal
410 linker length plays a key role in selecting the best activity of a fusion enzyme. Similar
411 observations have also been reported previously. For example, a fusion of *Marinobacter*
412 *aquaeolei* P450 (CYP153) and a CYP116B reductase showed 67% improvement of activity by
413 adding two extra amino acids in the linker (Hoffmann et al., 2016), and in another example, a ten
414 amino-acid linker was found to present the best activity in the fusion of P450_{cin} with its native
415 flavodoxin (CinC) (Belsare et al., 2014).

416 To experimentally reveal the difference caused by the linker length, we pursued the structural
417 analysis for G3 and G4 fusions which are selected with the best activities at the *in vitro*
418 conditions. The SEC-SAXS data and modeling results suggested they showed different structural
419 rigidities for the G4 fusion protein with a 12-aa linker and is less constrained, relative to the G3
420 fusion containing a 9-aa linker (Table 2, Figure 5D). This difference brought by the linker length
421 indicated its importance in maintaining the rigidity of a fusion complex as well as reaching the
422 best activity of a fusion protein. In addition to the linker length, the different ratios of P450 and
423 redox partners could change the P450 conversion in a wide range (Hawkes et al., 2010; Khatri et
424 al., 2017). Therefore, precision modulation of the *in vivo* P450-redox ratio presents a promising
425 strategy to improve the P450 conversion yield for microbial production systems (Li et al., 2020;
426 Schiffer et al., 2015).

427 Besides, the orientation of active sites in a fusion protein is another critical factor to achieve
428 improved catalysis over the non-fused enzymes. In the assessment of the enzyme orientation in a
429 fusion protein, we found reversing the order of CS and P450_{cin} in the fusion protein dramatically
430 decreased the catalytic efficiency (Table 3), and even did not show significant improvement of
431 the activity over the non-fusion control. Given that the key interface residues R102 and R346

432 (Madrona et al., 2014) of P450_{cin} for the constitution of P450_{cin}-Cdx were intact for both CS-
433 P450_{cin} and P450_{cin}-CS fusions (Supplementary Figure S3), we think this inefficient fusion
434 construction might be more likely attributed to their relative position of the active sites in two
435 domains. As the structural modeling predicted, the two active sites of CS and P450_{cin} showed an
436 unfavorable orientation in the P450_{cin}-CS fusion protein, which may increase the difficulty for
437 1,8-cineole to access the binding sites of P450_{cin} (Supplementary Figure S3). We also observed
438 similar results in another negative example that implemented the enzyme fusion strategy in
439 perillyl alcohol production by the hydroxylation of limonene (Supplementary Information). In
440 this case, structural modeling predicted unfavorable orientation of two active sites for limonene
441 synthase (LS) and CYP153A6 in the built fusion protein (Supplementary Figure S5B), and the
442 experimental results also did not show any improvement in perillyl alcohol production in five
443 fusion proteins engineered with different linker lengths (Supplementary Figure S5C).

444 The SAXS structural analysis suggested that the linker length can change the structural
445 flexibility of domains in a fusion protein, but it may not easily change the orientation of enzyme
446 active sites in a fusion complex due to the associated rigidity. Thus, for those fusion proteins
447 showing an unfavorable orientation between two active sites, the loop structure at the terminus of
448 the first enzyme might be a key to overcome the native rigidity of two domains and to facilitate
449 the favorable orientations in the fusion. In a comparison of positive and negative examples we
450 studied, we observed that each of two negative examples (LS-CYP153A6 and P450_{cin}-CS
451 fusions) shows a relatively short C-terminal loop of the first enzyme (i.e. LS has a 4-aa loop and
452 P450_{cin} has a 7-aa loop), while the first enzymes of positive examples (CS-P450_{cin} and EizS-
453 CYP170A1 fusions) have long C-terminal loops (i.e. CS has a 19-aa loop and EizS has a 21-aa

454 loop) (Supplementary Figure S6). Therefore, the engineering of terminal loops could be a
455 potential target to design fusion protein more adequately.

456 While engineering of fusion proteins shows a feasible approach for desirable enzymatic
457 characteristics, it is still challenging to achieve the optimal activities. For example, it is difficult
458 to precisely control the distance or orientation of enzymatic modules in a fusion protein. Also,
459 the correct folding of a large multidomain protein could be difficult. Many P450 enzymes from
460 plants are membrane-bound and have shown poor soluble expression in the bacterial hosts such
461 as *E. coli* (Moser and Pichler, 2019). Thus, more consideration would be needed when
462 engineering a fusion for eukaryotic terpene synthases and the membrane bound P450s in
463 heterologous hosts. For example, truncating plastidial targeting sequence was found to improve
464 the heterologous expression and catalytic efficiency of (4S)-limonene synthase from *Mentha*
465 *spicata* (spearmint) in *E. coli* (Hyatt et al., 2007; Williams et al., 1998). Also, modifying N-
466 terminal sequences of cytochrome P450 (CYP71D18, *M. spicata*) increased P450 expression as
467 well as limonene hydroxylation rate in *E. coli* and yeast (Haudenschild et al., 2000).

468 The successful construction of a fusion enzyme relies on many factors, including domain
469 order, inter-domain distance, domain orientation, and linker properties (Yu et al., 2015).
470 Although several modeling programs have been reported to facilitate the designing of linkers for
471 fusion protein engineering (Crasto and Feng, 2000; Liu et al., 2015), an in-depth structural
472 analysis could be more important to design the optimal linker and the enzyme orientations to
473 build an enzyme fusion with improved catalysis. Based on our experimental results and structural
474 modeling analysis for fusion enzymes with both positive and negative results, we found the key
475 factors in designing an efficient fusion protein include linker length, enzyme orientation, and
476 potentially the terminal loops of each domain. Therefore, the combination of these factors guided

477 by structural modeling would be an effective strategy to design and optimize the activity of a
478 fusion enzyme.

479 The efficiency of the P450 bioconversion of terpenoids to oxidized products observed in our
480 studies is still low for both non-fusion and fusion proteins. This low efficiency could be a result of
481 the relatively low percentage of active P450 as observed in the P450_{cin} example (Supplementary
482 Table S4). Interestingly, it is noted that the engineered fusion proteins could affect the functional
483 expression of the active portion of P450_{cin}. Compared with the non-fusion P450_{cin}, some fusions
484 (G2-G5) showed a lower percentage of the active P450_{cin} portion despite higher productivities for
485 hydroxycineole while other fusion (G1) showed a higher percentage of the active portion with
486 lower productivity. Further optimization of the P450 enzymes and the *in vivo* microbial production
487 system is necessary to improve the conversion yield, such as increasing the active P450 portion,
488 identifying more efficient redox partners and the ratio of P450 and redox partners (Hawkes et al.,
489 2010; Kimmich et al., 2007), engineering fusions of redox partners for enhanced electron transfer
490 (Bakkes et al., 2017, 2015), optimizing the metabolic pathway for terpene substrate overproduction
491 and co-factor balance, developing *in situ* extraction reagent (e.g. resins) to facilitate the collection
492 of oxidized products (Alonso-Gutierrez et al., 2013).

493

494 **5. Conclusions**

495 The functionalization of terpene molecules using cytochrome P450 enzymes presents
496 opportunities to produce various bioproducts that are frequently more value-added than the
497 original terpene itself. In this study, we developed a strategy to improve the terpene
498 hydroxylation efficiency by linking terpene synthase and P450 enzyme and facilitating the
499 accessibility of terpene molecules to P450 enzymes in heterologous microbial systems. We

500 demonstrated this strategy for monoterpene 1,8-cineole hydroxylation and achieved more than a
501 5-fold increase in hydroxycineole production using fusion proteins *in vitro* and 3-fold *in vivo*
502 over the control using individual enzymes. Structural characterization of these enzyme fusions
503 revealed that the length of the linker affects the flexibility, which eventually affects the catalytic
504 activity, of the fusion enzymes. We also applied the enzyme fusion strategy to the oxidation of a
505 sesquiterpene epi-isozizaene, in which up to 90-fold improvement in albaflavenol production
506 was achieved by the fusion enzyme when the overlay was used. Our results suggested that
507 engineering of fusion enzymes between terpene synthase and P450 shows a simple and efficient
508 strategy toward the heterologous production of oxidized terpenes. Additionally, the structure-
509 based prediction and evaluation would guide the design of fusion proteins with improved
510 catalysis.

511

512 **Acknowledgments**

513 This work was part of the DOE Joint BioEnergy Institute (<http://www.jbei.org>) supported by the
514 US Department of Energy, Office of Science, Office of Biological and Environmental Research,
515 through Contract DE-AC0205CH11231 between Lawrence Berkeley National Laboratory and
516 the US Department of Energy. SAXS data was collected at the SIBYLS beamline in the
517 Advanced Light Source, which is supported by DOE BES, by the DOE OBER IDAT program,
518 by NIH ALS-ENABLE (P30 GM124169) and by NIH S10OD018483. We would also like to
519 acknowledge the help of beamline staff, Daniel Rosenberg and Michal Hammel.

520

521 **Author contributions**

522 XW and TSL designed the experiments. XW performed the experiments and structural modeling.
523 JHP and ST performed the SAXS experiment. XW, TSL, JHP, and ST analyzed the data, wrote
524 the manuscript. All authors reviewed and edited the final manuscript.

525

526 **Competing interests**

527 TSL has a financial interest in Maple Bio.

528

529 **References**

530 Aaron, J.A., Lin, X., Cane, D.E., Christianson, D.W., 2010. Structure of epi-isozizaene synthase
531 from *Streptomyces coelicolor* A3(2), a platform for new terpenoid cyclization templates.,
532 *Biochemistry* 49, 1787–1797.

533 Aharoni, A., Jongsma, M.A., Bouwmeester, H.J., 2005. Volatile science? Metabolic engineering
534 of terpenoids in plants. *Trends Plant Sci.* 10, 594–602.

535 Alonso-Gutierrez, J., Chan, R., Batth, T.S., Adams, P.D., Keasling, J.D., Petzold, C.J., Lee, T.S.,
536 2013. Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol
537 production. *Metab. Eng.* 19, 33–41.

538 Avalos, J.L., Fink, G.R., Stephanopoulos, G., 2013. Compartmentalization of metabolic
539 pathways in yeast mitochondria improves the production of branched-chain alcohols. *Nat.*
540 *Biotechnol.* 31, 335.

541 Bakkes, P.J., Biemann, S., Bokel, A., Eickholt, M., Girhard, M., Urlacher, V.B., 2015. Design
542 and improvement of artificial redox modules by molecular fusion of flavodoxin and
543 flavodoxin reductase from *Escherichia coli*. *Sci. Rep.* 5, 12158.

544 Bakkes, P.J., Riehm, J.L., Sagadin, T., Rühlmann, A., Schubert, P., Biemann, S., Girhard, M.,

545 Hutter, M.C., Bernhardt, R., Urlacher, V.B., 2017. Engineering of versatile redox partner
546 fusions that support monooxygenase activity of functionally diverse cytochrome P450s. *Sci.*
547 *Rep.* 7, 9570.

548 Belsare, K.D., Ruff, A.J., Martinez, R., Shivange, A. V, Mundhada, H., Holtmann, D., Schrader,
549 J., Schwaneberg, U., 2014. P-LinK: A method for generating multicomponent cytochrome
550 P450 fusions with variable linker length. *Biotechniques* 57, 13–20.

551 Bergman, A., Siewers, V., 2016. Chapter 7 - Metabolic engineering strategies to convert
552 carbohydrates to aviation range hydrocarbons, in: Chuck, C.J.B.T.-B. for A. (Ed.), .
553 Academic Press, pp. 151–190.

554 Bernhardt, R., 2006. Cytochromes P450 as versatile biocatalysts. *J. Biotechnol.* 124, 128–145.

555 Brosey, C.A., Yan, C., Tsutakawa, S.E., Heller, W.T., Rambo, R.P., Tainer, J.A., Ivanov, I.,
556 Chazin, W.J., 2013. A new structural framework for integrating replication protein A into
557 DNA processing machinery. *Nucleic Acids Res.* 41, 2313–2327.

558 Chang, M.C.Y., Eachus, R.A., Trieu, W., Ro, D.-K., Keasling, J.D., 2007. Engineering
559 *Escherichia coli* for production of functionalized terpenoids using plant P450s. *Nat. Chem.*
560 *Biol.* 3, 274.

561 Cheng, A.-X., Lou, Y.-G., Mao, Y.-B., Lu, S., Wang, L.-J., Chen, X.-Y., 2007. Plant terpenoids:
562 biosynthesis and ecological functions. *J. Integr. Plant Biol.* 49, 179–186.

563 Classen, S., Hura, G.L., Holton, J.M., Rambo, R.P., Rodic, I., McGuire, P.J., Dyer, K., Hammel,
564 M., Meigs, G., Frankel, K.A., Tainer, J.A., 2013. Implementation and performance of
565 SIBYLS: a dual endstation small-angle X-ray scattering and macromolecular
566 crystallography beamline at the Advanced Light Source. *J. Appl. Crystallogr.* 46, 1–13.

567 Conrado, R.J., Varner, J.D., DeLisa, M.P., 2008. Engineering the spatial organization of

568 metabolic enzymes: mimicking nature's synergy. *Curr. Opin. Biotechnol.* 19, 492–499.

569 Crasto, C.J., Feng, J., 2000. LINKER: a program to generate linker sequences for fusion
570 proteins. *Protein Eng. Des. Sel.* 13, 309–312.

571 Dueber, J.E., Wu, G.C., Malmirchegini, G.R., Moon, T.S., Petzold, C.J., Ullal, A. V, Prather,
572 K.L.J., Keasling, J.D., 2009. Synthetic protein scaffolds provide modular control over
573 metabolic flux. *Nat. Biotechnol.* 27, 753–759.

574 Dyer, K.N., Hammel, M., Rambo, R.P., Tsutakawa, S.E., Rodic, I., Classen, S., Tainer, J.A.,
575 Hura, G.L., 2014. High-Throughput SAXS for the Characterization of Biomolecules in
576 Solution: A Practical Approach, in: Chen, Y.W. (Ed.), *Structural Genomics: General
577 Applications*. Humana Press, Totowa, NJ, pp. 245–258.

578 Fiser, A., Do, R.K.G., Šali, A., 2000. Modeling of loops in protein structures. *Protein Sci.* 9,
579 1753–1773.

580 Franke, D., Petoukhov, M. V, Konarev, P. V, Panjkovich, A., Tuukkanen, A., Mertens, H.D.T.,
581 Kikhney, A.G., Hajizadeh, N.R., Franklin, J.M., Jeffries, C.M., Svergun, D.I., 2017. *{\it*
582 *ATSAS 2.8}*: a comprehensive data analysis suite for small-angle scattering from
583 macromolecular solutions. *J. Appl. Crystallogr.* 50, 1212–1225.

584 Gao, X., Gao, F., Liu, D., Zhang, H., Nie, X., Yang, C., 2016. Engineering the methylerythritol
585 phosphate pathway in cyanobacteria for photosynthetic isoprene production from CO₂.
586 *Energy Environ. Sci.* 9, 1400–1411.

587 Guo, H., Yang, Y., Xue, F., Zhang, H., Huang, T., Liu, W., Liu, H., Zhang, F., Yang, M., Liu,
588 C., Lu, H., Zhang, Y., Ma, L., 2017. Effect of flexible linker length on the activity of fusion
589 protein 4-coumaroyl-CoA ligase::stilbene synthase. *Mol. Biosyst.* 13, 598–606.

590 Haudenschild, C., Schalk M FAU - Karp, F., Karp F FAU - Croteau, R., Croteau, R., 2000.

591 Functional expression of regiospecific cytochrome P450 limonene hydroxylases from mint
592 (*Mentha* spp.) in *Escherichia coli* and *Saccharomyces cerevisiae*. *Arch. Biochem. Biophys.*
593 379, 127–136.

594 Hawkes, D.B., Adams, G.W., Burlingame, A.L., Ortiz de Montellano, P.R., De Voss, J.J., 2002.
595 Cytochrome P450cin (CYP176A), isolation, expression, and characterization . *J. Biol.*
596 *Chem.* 277, 27725–27732.

597 Hawkes, D.B., Slessor, K.E., Bernhardt, P. V, De Voss, J.J., 2010. Cloning, expression and
598 purification of cindoxin, an unusual Fmn-containing cytochrome P450 redox partner.
599 *ChemBioChem* 11, 1107–1114.

600 Hoffmann, S.M., Weissenborn, M.J., Gricman, Ł., Notonier, S., Pleiss, J., Hauer, B., 2016. The
601 impact of linker length on P450 fusion constructs: activity, stability and coupling.
602 *ChemCatChem* 8, 1591–1597.

603 Hura, G.L., Menon, A.L., Hammel, M., Rambo, R.P., Poole II, F.L., Tsutakawa, S.E., Jenney Jr,
604 F.E., Classen, S., Frankel, K.A., Hopkins, R.C., Yang, S., Scott, J.W., Dillard, B.D., Adams,
605 M.W.W., Tainer, J.A., 2009. Robust, high-throughput solution structural analyses by small
606 angle X-ray scattering (SAXS). *Nat. Methods* 6, 606–612.

607 Hyatt, D.C., Youn, B., Zhao, Y., Santhamma, B., Coates, R.M., Croteau, R.B., Kang, C., 2007.
608 Structure of limonene synthase, a simple model for terpenoid cyclase catalysis. *Proc. Natl.*
609 *Acad. Sci.* 104, 5360 LP – 5365.

610 Jenkins, C.M., Waterman, M.R., 1994. Flavodoxin and NADPH-flavodoxin reductase from
611 *Escherichia coli* support bovine cytochrome P450c17 hydroxylase activities. *J. Biol. Chem.*
612 269, 27401–27408.

613 Kang, A., George, K.W., Wang, G., Baidoo, E., Keasling, J.D., Lee, T.S., 2016. Isopentenyl

614 diphosphate (IPP)-bypass mevalonate pathways for isopentenol production. *Metab. Eng.* 34,
615 25–35.

616 Karuppiah, V., Ranaghan, K.E., Leferink, N.G.H., Johannissen, L.O., Shanmugam, M., Ní
617 Cheallaigh, A., Bennett, N.J., Kearsey, L.J., Takano, E., Gardiner, J.M., van der Kamp,
618 M.W., Hay, S., Mulholland, A.J., Leys, D., Scrutton, N.S., 2017. Structural basis of
619 catalysis in the bacterial monoterpene synthases linalool synthase and 1,8-cineole synthase.
620 *ACS Catal.* 7, 6268–6282.

621 Khatri, Y., Schiffrin, A., Bernhardt, R., 2017. Investigating the effect of available redox protein
622 ratios for the conversion of a steroid by a myxobacterial CYP260A1. *FEBS Lett.* 591,
623 1126–1140.

624 Kimmich, N., Das, A., Sevrioukova, I., Meharena, Y., Sligar, S.G., Poulos, T.L., 2007. Electron
625 Transfer between Cytochrome P450cin and Its FMN-containing Redox Partner, Cindoxin. *J.*
626 *Biol. Chem.* 282, 27006–27011.

627 Klocke, J.A., Darlington, M. V, Balandrin, M.F., 1987. 1,8-Cineole (Eucalyptol), a mosquito
628 feeding and ovipositional repellent from volatile oil of *Hemizonia fitchii* (Asteraceae). *J.*
629 *Chem. Ecol.* 13, 2131–2141.

630 Kourtz, L., Dillon, K., Daughtry, S., Madison, L.L., Peoples, O., Snell, K.D., 2005. A novel
631 thiolase–reductase gene fusion promotes the production of polyhydroxybutyrate in
632 *Arabidopsis*. *Plant Biotechnol. J.* 3, 435–447.

633 Leita, B.A., Warden, A.C., Burke, N., O’Shea, M.S., Trimm, D., 2010. Production of p-cymene
634 and hydrogen from a bio-renewable feedstock–1,8-cineole (eucalyptus oil). *Green Chem.*
635 12, 70–76.

636 Li, S., Du, L., Bernhardt, R., 2020. Redox Partners: Function Modulators of Bacterial P450

637 Enzymes. Trends Microbiol. 28, 445–454.

638 Liu, C.-L., Tian, T., Alonso-Gutierrez, J., Garabedian, B., Wang, S., Baidoo, E.E.K., Benites, V.,
639 Chen, Y., Petzold, C.J., Adams, P.D., Keasling, J.D., Tan, T., Lee, T.S., 2018. Renewable
640 production of high density jet fuel precursor sesquiterpenes from *Escherichia coli*.
641 Biotechnol. Biofuels 11, 285.

642 Liu, C., Chin, J.X., Lee, D.-Y., 2015. SynLinker: an integrated system for designing linkers and
643 synthetic fusion proteins. Bioinformatics 31, 3700–3702.

644 Ljungcrantz, P., Carlsson, H., Mansson, M.O., Buckel, P., Mosbach, K., Buelow, L., 1989.
645 Construction of an artificial bifunctional enzyme, .beta.-galactosidase/galactose
646 dehydrogenase, exhibiting efficient galactose channeling. Biochemistry 28, 8786–8792.

647 Madrona, Y., Hollingsworth, S.A., Tripathi, S., Fields, J.B., Rwigema, J.-C.N., Tobias, D.J.,
648 Poulos, T.L., 2014. Crystal structure of cindoxin, the P450cin redox partner. Biochemistry
649 53, 1435–1446.

650 Meharena, Y.T., Li, H., Hawkes, D.B., Pearson, A.G., De Voss, J., Poulos, T.L., 2004. Crystal
651 structure of P450cin in a complex with its substrate, 1,8-cineole, a close structural
652 homologue to d-camphor, the substrate for P450cam,. Biochemistry 43, 9487–9494.

653 Mendez-Perez, D., Alonso-Gutierrez, J., Hu, Q., Molinas, M., Baidoo, E.E.K., Wang, G., Chan,
654 L.J.G., Adams, P.D., Petzold, C.J., Keasling, J.D., Lee, T.S., 2017. Production of jet fuel
655 precursor monoterpenoids from engineered *Escherichia coli*. Biotechnol. Bioeng. 114,
656 1703–1712.

657 Meynial Salles, I., Forchhammer, N., Croux, C., Girbal, L., Soucaille, P., 2007. Evolution of a
658 *Saccharomyces cerevisiae* metabolic pathway in *Escherichia coli*. Metab. Eng. 9, 152–159.

659 Moser, S., Pichler, H., 2019. Identifying and engineering the ideal microbial terpenoid

660 production host. *Appl. Microbiol. Biotechnol.* 103, 5501–5516.

661 Pateraki, I., Heskes, A.M., Hamberger, B., 2015. Cytochromes P450 for terpene functionalisation
662 and metabolic engineering BT - biotechnology of isoprenoids, in: Schrader, J., Bohlmann,
663 J. (Eds.), . Springer International Publishing, Cham, pp. 107–139.

664 Pelikan, M., Hura, G.L., Hammel, M., 2009. Structure and flexibility within proteins as
665 identified through small angle X-ray scattering. *Gen. Physiol. Biophys.* 28, 174–189.

666 Pham, S.Q., Pompidor, G., Liu, J., Li, X.-D., Li, Z., 2012. Evolving P450_{pyr} hydroxylase for
667 highly enantioselective hydroxylation at non-activated carbon atom. *Chem. Commun.* 48,
668 4618–4620.

669 Putnam, C.D., Hammel, M., Hura, G.L., Tainer, J.A., 2007. X-ray solution scattering (SAXS)
670 combined with crystallography and computation: defining accurate macromolecular
671 structures, conformations and assemblies in solution. *Q. Rev. Biophys.* 40, 191–285.

672 Rambo, R.P., Tainer, J.A., 2013. Accurate assessment of mass, models and resolution by small-
673 angle scattering. *Nature* 496, 477–481.

674 Rambo, R.P., Tainer, J.A., 2011. Characterizing flexible and intrinsically unstructured biological
675 macromolecules by SAS using the Porod-Debye law. *Biopolymers* 95, 559–571.

676 Redding-Johanson, A.M., Bath, T.S., Chan, R., Krupa, R., Szmidt, H.L., Adams, P.D., Keasling,
677 J.D., Soon Lee, T., Mukhopadhyay, A., Petzold, C.J., 2011. Targeted proteomics for
678 metabolic pathway optimization: Application to terpene production. *Metab. Eng.* 13, 194–
679 203.

680 Renault, H., Bassard, J.-E., Hamberger, B., Werck-Reichhart, D., 2014. Cytochrome P450-
681 mediated metabolic engineering: current progress and future challenges. *Curr. Opin. Plant*
682 *Biol.* 19, 27–34.

683 Roy, A., Yang, J., Zhang, Y., 2012. COFACTOR: an accurate comparative algorithm for
684 structure-based protein function annotation. *Nucleic Acids Res.* 40, W471–W477.

685 Sarria, S., Wong, B., Martín, H.G., Keasling, J.D., Peralta-Yahya, P., 2014. Microbial synthesis
686 of pinene. *ACS Synth. Biol.* 3, 466–475.

687 Schiffer, L., Anderko, S., Hobler, A., Hannemann, F., Kagawa, N., Bernhardt, R., 2015. A
688 recombinant CYP11B1 dependent *Escherichia coli* biocatalyst for selective cortisol
689 production and optimization towards a preparative scale. *Microb. Cell Fact.* 14, 25.

690 Schneidman-Duhovny, D., Hammel, M., Tainer, J.A., Sali, A., 2016. FoXS, FoXSDock and
691 MultiFoXS: Single-state and multi-state structural modeling of proteins and their complexes
692 based on SAXS profiles. *Nucleic Acids Res.* 44, W424–W429.

693 Schneidman-Duhovny, D., Hammel, M., Tainer, J.A., Sali, A., 2013. Accurate SAXS profile
694 computation and its assessment by contrast variation experiments. *Biophys. J.* 105, 962–
695 974.

696 Shaw, J.J., Berbasova, T., Sasaki, T., Jefferson-George, K., Spakowicz, D.J., Dunican, B.F.,
697 Portero, C.E., Narváez-Trujillo, A., Strobel, S.A., 2015. Identification of a fungal 1,8-
698 cineole synthase from *hypoxylon* sp. with specificity determinants in common with the
699 plant synthases. *J. Biol. Chem.* 290, 8511–8526.

700 Slessor, K.E., Hawkes, D.B., Farlow, A., Pearson, A.G., Stok, J.E., De Voss, J.J., 2012. An in
701 vivo cytochrome P450cin (CYP176A1) catalytic system for metabolite production. *J. Mol.*
702 *Catal. B Enzym.* 79, 15–20.

703 Urlacher, V.B., Girhard, M., 2019. Cytochrome P450 monooxygenases in biotechnology and
704 synthetic biology. *Trends Biotechnol.* 37, 882–897.

705 van Beilen, J.B., Holtackers, R., Lüscher, D., Bauer, U., Witholt, B., Duetz, W.A., 2005.

706 Biocatalytic production of perillyl alcohol from limonene by using a novel *Mycobacterium*
707 sp. cytochrome P450 alkane hydroxylase expressed in *Pseudomonas putida*. *Appl. Environ.*
708 *Microbiol.* 71, 1737 LP – 1744.

709 Williams, D.C., McGarvey, D.J., Katahira, E.J., Croteau, R., 1998. Truncation of limonene
710 synthase preprotein provides a fully active 'pseudomature' form of this monoterpene cyclase
711 and reveals the function of the amino-terminal arginine pair. *Biochemistry* 37, 12213–
712 12220.

713 Yang, J., Zhang, Y., 2015. I-TASSER server: new development for protein structure and
714 function predictions. *Nucleic Acids Res.* 43, W174–W181.

715 Yang, X., Li, T., Tang, K., Zhou, X., Lu, M., Ounkham, W.L., Spain, S.M., Frost, B.J., Lin, H.,
716 2017. Highly efficient conversion of terpenoid biomass to jet-fuel range cycloalkanes in a
717 biphasic tandem catalytic process. *Green Chem.* 19, 3566–3573.

718 Yu, K., Liu, C., Kim, B.-G., Lee, D.-Y., 2015. Synthetic fusion protein design and applications.
719 *Biotechnol. Adv.* 33, 155–164.

720 Zhang, Y., 2009. I-TASSER: Fully automated protein structure prediction in CASP8. *Proteins*
721 *Struct. Funct. Bioinforma.* 77, 100–113.

722 Zhao, B., Lei, L., Vassylyev, D.G., Lin, X., Cane, D.E., Kelly, S.L., Yuan, H., Lamb, D.C.,
723 Waterman, M.R., 2009. Crystal structure of albaflavenone monooxygenase containing a
724 moonlighting terpene synthase active site. *J. Biol. Chem.* 284, 36711–36719.

725 Zhao, B., Lin, X., Lei, L., Lamb, D.C., Kelly, S.L., Waterman, M.R., Cane, D.E., 2008.
726 Biosynthesis of the sesquiterpene antibiotic albaflavenone in *Streptomyces coelicolor*
727 A3(2). *J. Biol. Chem.* 283, 8183–8189.

728 Zuo, R., Zhang, Y., Jiang, C., Hackett, J.C., Loria, R., Bruner, S.D., Ding, Y., 2017. Engineered

729 P450 biocatalysts show improved activity and regio-promiscuity in aromatic nitration. Sci.
730 Rep. 7, 842.
731

732 **Table 1** Strains and plasmids used in this study

Strains	Description	Reference
CS	<i>E. coli</i> BL21 (DE3) with pSKB3-CS	This study
CinA	<i>E. coli</i> BL21 (DE3) with pSKB3-CinA	This study
CinC	<i>E. coli</i> BL21 (DE3) with pSKB3-CinC	This study
G1	<i>E. coli</i> BL21 (DE3) with pSKB3-CS-(GSG) ₁ -CinA	This study
G2	<i>E. coli</i> BL21 (DE3) with pSKB3-CS-(GSG) ₂ -CinA	This study
G3	<i>E. coli</i> BL21 (DE3) with pSKB3-CS-(GSG) ₃ -CinA	This study
G4	<i>E. coli</i> BL21 (DE3) with pSKB3-CS-(GSG) ₄ -CinA	This study
G5	<i>E. coli</i> BL21 (DE3) with pSKB3-CS-(GSG) ₅ -CinA	This study
Fpr	<i>E. coli</i> BL21 (DE3) with pSKB3-Fpr	This study
2pCin_Non-fusion	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-RBS-CinA-CinC	This study
CS-(GSG) ₁ -P450 _{cin}	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-(GSG) ₁ -CinA-CinC	This study
CS-(GSG) ₂ -P450 _{cin}	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-(GSG) ₂ -CinA-CinC	This study
CS-(GSG) ₃ -P450 _{cin}	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-(GSG) ₃ -CinA-CinC	This study
CS-(GSG) ₄ -P450 _{cin}	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-(GSG) ₄ -CinA-CinC	This study
CS-(GSG) ₅ -P450 _{cin}	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CS-(GSG) ₅ -CinA-CinC	This study
P450 _{cin} -(GSG) ₃ -CS	<i>E. coli</i> DH1 with JBEI-3122 + pTrc99a-trGPPS-CinA-(GSG) ₃ -CS-CinC	This study
2pEiz	<i>E. coli</i> DH1 with JBEI-2704 + JBEI-15862	This study
2pEiz_Non-fusion	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-RBS-CYP170A1-CinC	This study
EizS-(GSG) ₁ -CYP170A1	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-(GSG) ₁ -CYP170A1-CinC	This study
EizS-(GSG) ₂ -CYP170A1	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-(GSG) ₂ -CYP170A1-CinC	This study
EizS-(GSG) ₃ -CYP170A1	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-(GSG) ₃ -CYP170A1-CinC	This study
EizS-(GSG) ₄ -CYP170A1	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-(GSG) ₄ -CYP170A1-CinC	This study
EizS-(GSG) ₅ -CYP170A1	<i>E. coli</i> DH1 with JBEI-2704 + pTrc99a-EizS-(GSG) ₅ -CYP170A1-CinC	This study
Plasmids	Description	Reference

pSKB3	Modified pET-28a	(Kang et al., 2016)
JBEI-3122	pBbA5c-MTSA-T1-MBI	(Alonso-Gutierrez et al., 2013)
JBEI-15065	pTrc99a-GPPS-CS _{Str}	(Mendez-Perez et al., 2017)
JBEI-2704	pBbA5c-MevT-T1-MBIS	(Redding-Johanson et al., 2011)
JBEI-15862	pTrc99a-coEizS	(Liu et al., 2018)
JPUB_016968	pSKB3-CS	This study
JPUB_016970	pSKB3-CinA	This study
JPUB_016972	pSKB3-CinC	This study
JPUB_016974	pSKB3-CS-G1-CinA	This study
JPUB_016976	pSKB3-CS-G2-CinA	This study
JPUB_016978	pSKB3-CS-G3-CinA	This study
JPUB_016980	pSKB3-CS-G4-CinA	This study
JPUB_016982	pSKB3-CS-G5-CinA	This study
JPUB_016984	pSKB3-Fpr	This study
JPUB_016986	pTrc99a-trGPPS-CS-RBS-CinA-CinC	This study
JPUB_016988	pTrc99a-trGPPS-CS-(GSG) ₁ -CinA-CinC	This study
JPUB_016990	pTrc99a-trGPPS-CS-(GSG) ₂ -CinA-CinC	This study
JPUB_016992	pTrc99a-trGPPS-CS-(GSG) ₃ -CinA-CinC	This study
JPUB_016994	pTrc99a-trGPPS-CS-(GSG) ₄ -CinA-CinC	This study
JPUB_016996	pTrc99a-trGPPS-CS-(GSG) ₅ -CinA-CinC	This study
JPUB_016998	pTrc99a-trGPPS-CinA-(GSG) ₃ -CS-CinC	This study
JPUB_017000	pTrc99a-EizS-RBS-CYP170A1-CinC	This study
JPUB_017002	pTrc99a-EizS-(GSG) ₁ -CYP170A1-CinC	This study
JPUB_017003	pTrc99a-EizS-(GSG) ₂ -CYP170A1-CinC	This study
JPUB_017005	pTrc99a-EizS-(GSG) ₃ -CYP170A1-CinC	This study
JPUB_017007	pTrc99a-EizS-(GSG) ₄ -CYP170A1-CinC	This study
JPUB_017009	pTrc99a-EizS-(GSG) ₅ -CYP170A1-CinC	This study

734 **Table 2** SAXS Data collection and metrics

SEC-SAXS Data	G3 monomer	G3 dimer	G4 monomer	G4 dimer
Nomenclature	222	221	232	231
Porod Debye (Px)	3.9	3.4	3.3	3.3
Low q (\AA^{-1})	0.0137	0.0158	0.0209	0.0137
High q (\AA^{-1})	0.366	0.366	0.366	0.366
Reciprocal Rg (\AA)	33	44	36	46
Reciprocal I(0) (detector units)	111	191	374	2,940
Real space Rg (\AA)	33	44	35	46
Real space I(0) (detector units)	111	191	374	2,940
Dmax (\AA)	96	150	106	158
Vc Molecular Mass (kDa)	85	147	85	153
Theoretical Mass (kDa) [dimer]	86.6	[173]	86.7	[173]

735

736

737

738

739

740

741

742

743

744

745 **Table 3** Characterization of the fusion protein with the reversed orientation of enzymes (P450_{cin}-
 746 CS) during the *in vivo* hydroxycineole production

	1,8-Cineole (mg/L)		Hydroxycineole (mg/L) *	
	With overlay	Without overlay	With overlay	Without overlay
Non-fusion	88 ± 14	2 ± 0	10 ± 0	18 ± 1
CS-P450 _{cin}	86 ± 1	3 ± 1	32 ± 1	56 ± 1
P450 _{cin} -CS	42 ± 10	1 ± 0	8 ± 0	21 ± 1

747 Data are represented as mean ± standard deviation of triplicates.


748 * Hydroxycineole concentrations are reported based on the equivalent concentration of 1,8-
 749 cineole.

750


751 **Figures**

752

Non-fusion



Fusion



753

Graphical abstract

755

756

757

758

759


760

761

762

763

764



765

766 **Figure 1** Engineering enzyme fusions by linking terpene synthase (CS, EizS) and P450 enzyme


767 (CYP) for the production of oxidized terpenoids. GPP, geranyl pyrophosphate; FPP, farnesyl

768 pyrophosphate; CS, 1,8-cineole synthase; EizS, epi-isozizaene synthase; GPPS, geranyl


769 pyrophosphate synthase.

770

(A) Non fusion




(B) CS-P450_{cin}




771

772 **Figure 2** Structural prediction of CS-P450_{cin} fusion protein. (A) Structures of non-fused enzymes
773 of P450_{cin} and CS monomer aligned with the predicted structure of CS-P450_{cin} fusion. (B)
774 Predicted structure of the CS-P450_{cin} fusion protein with a (GSG)₃ peptide linker (G3), C-score
775 of I-TASSER = -2.74. P450_{cin}, red cartoon; CS, blue cartoon; (GSG)₃ linker, green loop; Heme,
776 pink stick molecule; Residues of active sites, color stick molecules.



777
 778 **Figure 3** *In vitro* production of hydroxycineole. (A) *In vitro* two-step reaction from GPP. (B)
 779 SDS-PAGE gel of purified non-fusion and fusions for CS and P450_{cin}. Fusions of CS and P450_{cin}
 780 (G1 to G5) were engineered with 1 to 5 repeats of GSG peptide linker. Size of purified proteins:
 781 CS, 40.71 KDa; P450_{cin} (CinA), 48.25 KDa; G1, 86.16 KDa; G2, 86.37 KDa; G3, 86.57 KDa;
 782 G4, 86.77 KDa; G5, 86.97 KDa. (C) *In vitro* time-course production of cineole and
 783 hydroxycineole from GPP substrate with purified proteins. Hydroxycineole concentrations are
 784 reported based on the equivalent concentration of 1,8-cineole. Error bars indicate one standard
 785 deviation ($n = 3$). (D) Hydroxylation ratio of *in vitro* reaction after 5 hours. The hydroxylation
 786 ratio is the molar ratio of hydroxycineole out of the total generated terpenes (1,8-cineole and
 787 hydroxycineole).
 788



789

790 **Figure 4** *In vivo* production of hydroxycineole by *E. coli* DH1 strains with engineered enzyme

791 fusions. (A) Metabolic pathway of hydroxycineole production from glucose using enzyme


792 fusions of CS and P450_{cin}, CS-(GSG)_n-P450_{cin} (n = 1–5). (B) OD₆₀₀ of production strains after 48

793 hours. (C) Production of 1,8-cineole and hydroxycineole with or without the solvent overlay.

794 Hydroxycineole concentrations are reported based on the equivalent concentration of 1,8-cineole.


795 Error bars indicate one standard deviation of triplicates.

796



798

799 **Figure 5** SAXS analysis of enzyme fusions. (A) SEC-SAXS chromatogram of G3 and G4 fusion
 800 proteins. The horizontal line indicates peak(s) that were further analyzed. (B) Reciprocal space
 801 SAXS curves after SVD, representing scattering from monomer and dimer for G3 and G4 enzyme
 802 fusions, overlaid with curves predicted from models that best fit the experimental data (red curves).
 803 χ^2 fit of models is shown. (C) Corresponding real space SAXS curves with experimental and model
 804 curves overlaid. (D) Ab initio shape predictions overlaid with the best-fitting model. Models were
 805 based on 1,8-cineole synthase (PDB ID: 5NX6, blue) and P450_{cin} (PDB ID: 1T2B, red).



806

807 **Figure 6** Production of oxidized epi-isozizaene with engineered enzyme fusions in *E. coli* DH1.

808 (A) Metabolic pathway of oxidized epi-isozizaene production from glucose using enzyme

809 fusions of EizS and CYP170A1, EizS-(GSG)_n-CYP170A1 (n = 1–5); FPP, farnesyl

810 pyrophosphate. (B) OD₆₀₀ of production strains after 72 hours. (C) Production of epi-isozizaene

811 with or without the solvent overlay. (D) Production of oxidized epi-isozizaene (albaflavenol,

812 albaflavenone) with or without the solvent overlay. The concentrations of epi-isozizaene,

813 albaflavenol, and albaflavenone are reported based on the equivalent concentration of (-)-trans

814 caryophyllene. Error bars indicate one standard deviation of triplicates.